Compare TIL & FEIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIL | FEIM |
|---|---|---|
| Founded | 2018 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 348.4M |
| IPO Year | 2021 | N/A |
| Metric | TIL | FEIM |
|---|---|---|
| Price | $11.39 | $48.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $100.67 | $42.50 |
| AVG Volume (30 Days) | 62.3K | ★ 287.2K |
| Earning Date | 11-13-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 163.76 |
| EPS | N/A | ★ 2.17 |
| Revenue | N/A | ★ $69,852,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.90 |
| P/E Ratio | ★ N/A | $22.22 |
| Revenue Growth | N/A | ★ 16.06 |
| 52 Week Low | $10.69 | $13.69 |
| 52 Week High | $42.79 | $49.48 |
| Indicator | TIL | FEIM |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 74.68 |
| Support Level | $10.72 | $41.11 |
| Resistance Level | $11.85 | $46.21 |
| Average True Range (ATR) | 0.60 | 3.74 |
| MACD | 0.25 | 1.72 |
| Stochastic Oscillator | 60.52 | 93.79 |
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.